TICKERNERD
Menu
SLXNSLXNHealthcare · Biotechnology

SLXN Stock Forecast: Silexion Therapeutics Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.44

The 2 Wall Street analysts covering Silexion Therapeutics Corp. hold a median 12-month price target of $60 — +13677.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$2.4M
Ticker Nerd rank
53 / 100
Median analyst target
$60
Analysts covering
2
Revenue$0.0
Operating income−$3.7M
Net income−$3.6M
Free cash flow−$2.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

SLXN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Silexion Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
86
Growth
70
Revisions
67
Issuance
54
Volatility
50
Momentum
18
Value
13
Quality
13

Size (98): Smaller than most of the companies we track.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLXN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLXN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $60Median $60High $60

The green dot is the last close — the median target sits +13677.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Dec 2025Litchfield HillsInitiatesBuy$6.00
20 Mar 2025Maxim GroupMaintainsBuy—
1 Nov 2024Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLXN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SLXN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Silexion Therapeutics Corp. (SLXN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
54.4×

Cheaper than 2% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−457.6%

Higher than 3% of US stocks

Return on assets
−165.1%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Silexion Therapeutics Corp. (SLXN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Silexion Therapeutics Corp. has a market value of $2.4M and an enterprise value of $1.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$14.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.4M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Silexion Therapeutics Corp. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

SLXN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLXNSilexion Therapeutics Corp.$2.4M
53
CDTCDT Equity, Inc.$2.4M
11
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44
SPRCSciSparc Ltd.$2.6M
19
CMNDClearmind Medicine, Inc.$2.7M
6
ARTLArtelo Biosciences, Inc.$2.2M
15
PPCBPropanc Biopharma, Inc.$2.1M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Silexion Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLXN news & analysis

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

GlobeNewsWire · 9 Sept 2026neutral

Silexion Therapeutics announced that its management team, including Chief Scientific and Development Officer Dr. Mitchell Shirvan, will present at two industry conferences in Boston in September 2026: the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9 and the 8th Annual RAS-Targeted Drug Development Summit on September 10.

Why it matters — For SLXN watchers, these conference presentations provide the company with opportunities to present its RNAi platform for KRAS-driven cancers to potential partners and investors.

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

Silexion Therapeutics reported its second quarter 2026 financial results and provided a business update. The company advanced its lead candidate SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, initiating the trial at Tel Aviv Sourasky Medical Center in July 2026 after receiving clinical trial authorizations from regulators in Israel and Germany.

Why it matters — This update signals a key clinical milestone for SLXN, as SIL204 has moved from regulatory preparation into an active patient-enrolling Phase 2/3 trial with regulatory approvals secured in two jurisdictions.

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

GlobeNewsWire · 12 Aug 2026neutral

Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares (or equivalents) and series E warrants at a combined price of $0.65 per share and accompanying warrant. The warrants are exercisable immediately at $0.65 per share and expire five years from issuance, with closing expected on or about August 13, 2026, subject to customary conditions.

Why it matters — This capital raise provides Silexion with additional funding for its clinical-stage RNAi programs targeting KRAS-driven cancers, and the accompanying warrants could affect future share count.

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

GlobeNewsWire · 4 Aug 2026positive

Silexion Therapeutics reported new positive preclinical findings demonstrating multi-mechanism immune sensitization by SIL204 in KRAS-driven cancers. The company plans to present the SIL-204 data at a leading cancer symposium focused on the latest science in gastrointestinal cancers.

Why it matters — A SLXN watcher would care because promising preclinical results on its SIL-204 candidate, along with a presentation at a major cancer symposium, could mark progress in advancing its pipeline for KRAS-driven cancers.

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

GlobeNewsWire · 29 July 2026positive

Silexion Therapeutics announced the successful initiation of its Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center, clearing the site to begin patient screening for locally advanced pancreatic cancer. The milestone marks the program's move from regulatory preparation into active clinical execution, with additional trial sites in Israel and Germany expected to join in the coming months.

Why it matters — This milestone signals that Silexion's lead siRNA candidate, SIL204, is advancing from the regulatory phase into active patient dosing and clinical execution for locally advanced pancreatic cancer.

FAQ

Frequently asked questions about SLXN stock

What is the SLXN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Silexion Therapeutics Corp. have a median 12-month price target of $60, with estimates ranging from $60 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLXN stock a buy right now?

Of the 2 analysts covering Silexion Therapeutics Corp., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Silexion Therapeutics Corp. 53 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLXN?

As at 19 Sept 2026, Silexion Therapeutics Corp. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will SLXN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +13677.3% from the last close, and Ticker Nerd's factor model ranks Silexion Therapeutics Corp. 53 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLXN stock forecast for 2030?

No analyst covering Silexion Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLXN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $60 over the next 12 months.

What does Silexion Therapeutics Corp. do?

Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers.

What is the latest news on SLXN?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences". Silexion Therapeutics announced that its management team, including Chief Scientific and Development Officer Dr. Mitchell Shirvan, will present at two industry conferences in Boston in September 2026: the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9 and the 8th Annual RAS-Targeted Drug Development Summit on September 10.

Company

About Silexion Therapeutics Corp.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company’s current work centers on treating difficult solid tumors, with an emphasis on pancreatic cancer and other malignancies linked to KRAS mutations. Its pipeline includes SIL204, a lead siRNA-based candidate designed to silence mutant KRAS using both local and systemic delivery approaches, as well as additional product programs under its LODER delivery platform. Silexion Therapeutics Corp. operates as an oncology-focused developer of targeted genetic therapies, combining drug design and delivery technology to address areas of unmet medical need in cancer treatment.

CEO Mr. Ilan Hadar M.B.A. · 13 employees · Israel · https://silexion.com